(P133) Spinal Cord Dose Comparison With and Without Contrast Density Correction on CT Myelogram Simulations for Patients Treated With Stereotactic Body or Conventional Radiotherapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

These data suggest that the use of a CT myelogram with simulation significantly underestimates the spinal cord maximum and mean doses. The clinical significance of this finding is uncertain, and this study is limited by its small sample size. Density correction should be further investigated in a larger study, given the high doses used in SBRT and potential morbidity of spinal cord injury.

Sukhjeet S. Batth, MD, MS, Raymond Chiu, CMD, Nicholas Trakul, MD, PhD; USC Norris Cancer Center

PURPOSE/OBJECTIVES: Patients treated with stereotactic body radiotherapy (SBRT, also known as stereotactic ablative radiotherapy) or conventional RT to spinal targets often undergo a computed tomography (CT) simulation with a myelogram to accurately identify the spinal cord. Treatment planning algorithms use Hounsfield units and a CT density table to calculate radiation dose. Accuracy of these calculations may be improved by correcting for the contrast’s actual density, which is not present at the time of treatment delivery. We hypothesize that the spinal cord receives a higher radiation dose than calculated after correction of the contrast’s physical density.

MATERIALS AND METHODS: CT simulations with a myelogram for treatment of 10 spinal targets from nine patients were retrospectively reviewed. Seven of these targets were treated with SBRT, one was treated with intensity-modulated RT, and two were treated with three-dimensional conformal RT. The contrast from the myelogram was contoured in the treatment planning software, and the physical density was adjusted to 1 g/cm3. The uncorrected spinal cord maximum and mean doses were then compared with the doses after correction of the density. A two-tailed, paired t-test was used to compare the calculated doses.

RESULTS: The corrected spinal cord doses were all significantly higher than the uncorrected doses based on paired t-test for the maximum dose (P = .0073) and the mean dose (P = .00087). The mean maximum cord dose was 2,065 cGy and 2,077 cGy after correction. The mean of the average cord dose was 1,302 cGy and 1,315 cGy after correction.

CONCLUSIONS: These data suggest that the use of a CT myelogram with simulation significantly underestimates the spinal cord maximum and mean doses. The clinical significance of this finding is uncertain, and this study is limited by its small sample size. Density correction should be further investigated in a larger study, given the high doses used in SBRT and potential morbidity of spinal cord injury.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content